Publication

SEROLOGICAL MARKERS OF DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS

SPRONK, P. E., Limburg, P. & Kallenberg, C., Apr-1995, In : Lupus. 4, 2, p. 86 - 94 9 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

SPRONK, P. E., Limburg, P., & Kallenberg, C. (1995). SEROLOGICAL MARKERS OF DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS. Lupus, 4(2), 86 - 94.

Author

SPRONK, P.E. ; Limburg, Piet ; Kallenberg, Cees. / SEROLOGICAL MARKERS OF DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS. In: Lupus. 1995 ; Vol. 4, No. 2. pp. 86 - 94.

Harvard

SPRONK, PE, Limburg, P & Kallenberg, C 1995, 'SEROLOGICAL MARKERS OF DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS', Lupus, vol. 4, no. 2, pp. 86 - 94.

Standard

SEROLOGICAL MARKERS OF DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS. / SPRONK, P.E.; Limburg, Piet; Kallenberg, Cees.

In: Lupus, Vol. 4, No. 2, 04.1995, p. 86 - 94.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

SPRONK PE, Limburg P, Kallenberg C. SEROLOGICAL MARKERS OF DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS. Lupus. 1995 Apr;4(2):86 - 94.


BibTeX

@article{b82f512d43aa4ffa980d4fc7b747459f,
title = "SEROLOGICAL MARKERS OF DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS",
abstract = "When measured serially by Farr assay at a frequency of approximately once a month, changes in levels of anti-dsDNA appear to be a good predictor of clinical disease activity. Although the role of antibodies to the RNA component of snRNP awaits further studies, measurement of anti-UsnRNP antibody levels seems to be of limited value in monitoring lupus patients in clinical practice. The same holds for antibodies to SSA (Re) and anti-histone antibodies. More recently described antibodies to C1q are probably useful in the follow-up of SLE patients suspected of proliferative renal involvement. The best alternative to measuring levels of the antibodies mentioned before is probably serial analysis of activation of the complement cascade. Levels of complement factors like C3, C4 and, functionally, CH50 remain a useful parameter for monitoring disease activity in SLE, although fluctuations in anti-dsDNA as measured by Farr assay seem superior with respect to sensitivity and specificity for an ensuing relapse. Despite the problems in sampling, measuring levels of activated split products of complement factors like C3a, C3d or C5a may prove to be a valuable tool in the follow-up of lupus patients. The involvement of the endothelial surface is illustrated by rising sVCAM-1 levels prior to relapses in SLE. Although one could expect that subsequent inflammation should be reflected by increased levels of inflammatory molecules like CRP and IL-6, the use of these molecules as predictors of lupus activity seems limited. Interferon-alpha as a direct reflector of the effector phase seems, however, rather promising in this respect and awaits longitudinal studies to analyse the possible relation with clinical disease activity and other serological parameters.",
keywords = "REVIEW, SEROLOGY, AUTOANTIBODIES, ANTI-DNA, SLE, HEPARAN SULFATE REACTIVITY, COMPLEMENT RECEPTOR TYPE-1, CONGENITAL HEART-BLOCK, ANTI-DNA ANTIBODIES, DOUBLE-STRANDED DNA, IMMUNE-COMPLEXES, NUCLEAR RIBONUCLEOPROTEIN, LONG-TERM, CLINICAL-SIGNIFICANCE, INTERFERON-ALPHA",
author = "P.E. SPRONK and Piet Limburg and Cees Kallenberg",
note = "Review 3",
year = "1995",
month = "4",
language = "English",
volume = "4",
pages = "86 -- 94",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - SEROLOGICAL MARKERS OF DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS

AU - SPRONK, P.E.

AU - Limburg, Piet

AU - Kallenberg, Cees

N1 - Review 3

PY - 1995/4

Y1 - 1995/4

N2 - When measured serially by Farr assay at a frequency of approximately once a month, changes in levels of anti-dsDNA appear to be a good predictor of clinical disease activity. Although the role of antibodies to the RNA component of snRNP awaits further studies, measurement of anti-UsnRNP antibody levels seems to be of limited value in monitoring lupus patients in clinical practice. The same holds for antibodies to SSA (Re) and anti-histone antibodies. More recently described antibodies to C1q are probably useful in the follow-up of SLE patients suspected of proliferative renal involvement. The best alternative to measuring levels of the antibodies mentioned before is probably serial analysis of activation of the complement cascade. Levels of complement factors like C3, C4 and, functionally, CH50 remain a useful parameter for monitoring disease activity in SLE, although fluctuations in anti-dsDNA as measured by Farr assay seem superior with respect to sensitivity and specificity for an ensuing relapse. Despite the problems in sampling, measuring levels of activated split products of complement factors like C3a, C3d or C5a may prove to be a valuable tool in the follow-up of lupus patients. The involvement of the endothelial surface is illustrated by rising sVCAM-1 levels prior to relapses in SLE. Although one could expect that subsequent inflammation should be reflected by increased levels of inflammatory molecules like CRP and IL-6, the use of these molecules as predictors of lupus activity seems limited. Interferon-alpha as a direct reflector of the effector phase seems, however, rather promising in this respect and awaits longitudinal studies to analyse the possible relation with clinical disease activity and other serological parameters.

AB - When measured serially by Farr assay at a frequency of approximately once a month, changes in levels of anti-dsDNA appear to be a good predictor of clinical disease activity. Although the role of antibodies to the RNA component of snRNP awaits further studies, measurement of anti-UsnRNP antibody levels seems to be of limited value in monitoring lupus patients in clinical practice. The same holds for antibodies to SSA (Re) and anti-histone antibodies. More recently described antibodies to C1q are probably useful in the follow-up of SLE patients suspected of proliferative renal involvement. The best alternative to measuring levels of the antibodies mentioned before is probably serial analysis of activation of the complement cascade. Levels of complement factors like C3, C4 and, functionally, CH50 remain a useful parameter for monitoring disease activity in SLE, although fluctuations in anti-dsDNA as measured by Farr assay seem superior with respect to sensitivity and specificity for an ensuing relapse. Despite the problems in sampling, measuring levels of activated split products of complement factors like C3a, C3d or C5a may prove to be a valuable tool in the follow-up of lupus patients. The involvement of the endothelial surface is illustrated by rising sVCAM-1 levels prior to relapses in SLE. Although one could expect that subsequent inflammation should be reflected by increased levels of inflammatory molecules like CRP and IL-6, the use of these molecules as predictors of lupus activity seems limited. Interferon-alpha as a direct reflector of the effector phase seems, however, rather promising in this respect and awaits longitudinal studies to analyse the possible relation with clinical disease activity and other serological parameters.

KW - REVIEW

KW - SEROLOGY

KW - AUTOANTIBODIES

KW - ANTI-DNA

KW - SLE

KW - HEPARAN SULFATE REACTIVITY

KW - COMPLEMENT RECEPTOR TYPE-1

KW - CONGENITAL HEART-BLOCK

KW - ANTI-DNA ANTIBODIES

KW - DOUBLE-STRANDED DNA

KW - IMMUNE-COMPLEXES

KW - NUCLEAR RIBONUCLEOPROTEIN

KW - LONG-TERM

KW - CLINICAL-SIGNIFICANCE

KW - INTERFERON-ALPHA

M3 - Review article

VL - 4

SP - 86

EP - 94

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 2

ER -

ID: 2021745